These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 2134116)
41. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies. Saletu B; Grünberger J; Linzmayer L; Stöhr H Int J Clin Pharmacol Res; 1984; 4(2):95-107. PubMed ID: 6469443 [TBL] [Abstract][Full Text] [Related]
42. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Linzmayer L; Semlitsch HV; Saletu B; Böck G; Saletu-Zyhlarz G; Zoghlami A; Gruber D; Metka M; Huber J; Oettel M; Gräser T; Grünberger J Arzneimittelforschung; 2001; 51(3):238-45. PubMed ID: 11304940 [TBL] [Abstract][Full Text] [Related]
43. Improvement in verbal memory after withdrawal of carbamazepine and valproate in patients with well-controlled epilepsy: a randomized, double-blind study. Hessen E; Lossius MI; Gjerstad L Acta Neurol Scand; 2011 Jun; 123(6):385-9. PubMed ID: 20955400 [TBL] [Abstract][Full Text] [Related]
44. Tracking the cognitive pharmacodynamics of psychoactive substances with combinations of behavioral and neurophysiological measures. Gevins A; Smith ME; McEvoy LK Neuropsychopharmacology; 2002 Jan; 26(1):27-39. PubMed ID: 11751030 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of the effects of anti-motion sickness drugs on subjective sleepiness and cognitive performance of healthy males. Weerts AP; Pattyn N; Van de Heyning PH; Wuyts FL J Psychopharmacol; 2014 Jul; 28(7):655-64. PubMed ID: 24346808 [TBL] [Abstract][Full Text] [Related]
46. Flunitrazepam-induced changes in neurophysiological, behavioural, and subjective measures used to assess sedation. Lucchesi LM; Pompéia S; Manzano GM; Kohn AF; Galduroz JC; Bueno OF; Tufik S Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):525-33. PubMed ID: 12691789 [TBL] [Abstract][Full Text] [Related]
47. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R Epilepsia; 2006 Jul; 47(7):1121-7. PubMed ID: 16886974 [TBL] [Abstract][Full Text] [Related]
48. Modafinil improves information processing speed and increases energetic resources for orientation of attention in narcoleptics: double-blind, placebo-controlled ERP studies with low-resolution brain electromagnetic tomography (LORETA). Saletu M; Anderer P; Saletu-Zyhlarz GM; Mandl M; Saletu B; Zeitlhofer J Sleep Med; 2009 Sep; 10(8):850-8. PubMed ID: 19342295 [TBL] [Abstract][Full Text] [Related]
49. [Quantitative EEG and event-related potential P300 analysis oxiracetam injection curative effect in the treatment of delayed encephalopathy after acutecarbon monoxide poisoning]. Sun ML; Shi DM; Yin HN; Pan XB; Liu WG Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2018 Feb; 36(2):158-160. PubMed ID: 29699023 [No Abstract] [Full Text] [Related]
50. Influence of major antiepileptic drugs on neuropsychological function: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients on monotherapy. Hessen E; Lossius MI; Reinvang I; Gjerstad L J Int Neuropsychol Soc; 2007 May; 13(3):393-400. PubMed ID: 17445287 [TBL] [Abstract][Full Text] [Related]
51. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Park SP; Hwang YH; Lee HW; Suh CK; Kwon SH; Lee BI Epilepsy Behav; 2008 Jan; 12(1):102-8. PubMed ID: 17945539 [TBL] [Abstract][Full Text] [Related]
52. Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. Saletu M; Anderer P; Semlitsch HV; Saletu-Zyhlarz GM; Mandl M; Zeitlhofer J; Saletu B Psychiatry Res; 2007 Jan; 154(1):69-84. PubMed ID: 17187965 [TBL] [Abstract][Full Text] [Related]
53. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. Dysken MW; Katz R; Stallone F; Kuskowski M J Neuropsychiatry Clin Neurosci; 1989; 1(3):249-52. PubMed ID: 2521069 [TBL] [Abstract][Full Text] [Related]
54. Cognitive improvement in clinical trials with nootropic drugs: when can it be expected and how to clarify its meaning. Gainotti G; Benedetti N; Caltagirone C; Nocentini U Clin Neuropharmacol; 1986; 9 Suppl 3():S65-9. PubMed ID: 3297320 [TBL] [Abstract][Full Text] [Related]
55. Psychotropic drug induced changes in auditory averaged evoked potentials: results of a double-blind trial using an objective fully automated AEP analysis method. Herrmann WM; Hofmann W; Kubicki S Int J Clin Pharmacol Ther Toxicol; 1981 Feb; 19(2):56-62. PubMed ID: 7216551 [No Abstract] [Full Text] [Related]
56. A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guaraná in humans. Haskell CF; Kennedy DO; Wesnes KA; Milne AL; Scholey AB J Psychopharmacol; 2007 Jan; 21(1):65-70. PubMed ID: 16533867 [TBL] [Abstract][Full Text] [Related]
57. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880 [TBL] [Abstract][Full Text] [Related]
58. [A comparative study of the nootropic properties of piracetam and oxiracetam]. Krylova IN; Antonova LV; Kamenskiĭ AA; Iasnetsov VV Farmakol Toksikol; 1991; 54(1):14-6. PubMed ID: 1860490 [TBL] [Abstract][Full Text] [Related]
59. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. Brown ES; Gorman AR; Hynan LS J Clin Psychopharmacol; 2007 Oct; 27(5):498-502. PubMed ID: 17873684 [TBL] [Abstract][Full Text] [Related]
60. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Vayısoğlu S; Anıl Yağcıoğlu AE; Yağcıoğlu S; Karahan S; Karcı O; Gürel SC; Yazıcı MK Schizophr Res; 2013 Jan; 143(1):207-14. PubMed ID: 23217729 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]